Does everyone lose weight on Wegovy, and what affects your results?

What the trial data actually shows about the spread of results

The STEP 1 trial is the foundation for what we know about semaglutide 2.4mg in adults with obesity. Roughly 2,000 adults without type 2 diabetes participated, and after 68 weeks the semaglutide group lost approximately 15% of body weight on average compared with around 2.4% in the placebo group. That gap is striking. What the headline average does not show, though, is the distribution underneath it.

Some participants lost more than 20% of their starting weight. Others lost closer to 5%. A meaningful minority (estimates in the published literature put this at roughly one in ten participants) lost less than 5% at the maintenance dose, a threshold the NICE appraisal of semaglutide (TA875) uses when reviewing whether continuing treatment remains appropriate. Clinical trials report averages because that is how trial statistics work; your result is a single data point, not an average.

The STEP programme also confirmed that weight loss tends to continue through the titration period and beyond, with most participants still losing weight at week 68. Stopping early, whether because of side effects or another reason, cuts that trajectory short. Understanding how Wegovy supports weight loss through the full titration schedule matters for setting realistic expectations from the start.

Biological reasons some people respond less to semaglutide

Wegovy works by activating GLP-1 receptors, which reduces appetite, slows the rate at which the stomach empties, and shifts the body's energy balance. But GLP-1 receptor density and sensitivity vary between individuals, and this appears to explain at least part of the variation in response. Genetics play a role that researchers are still mapping.

Metabolic starting point matters too. People with a higher baseline insulin resistance or with certain hormonal conditions may find their appetite suppression less pronounced, or that weight loss plateaus earlier. Body weight itself is regulated by multiple overlapping systems (hunger hormones, reward pathways, sleep quality, stress cortisol) and Wegovy targets one of them directly. For people where the others are particularly dominant, the effect can be smaller.

This is not a reason to dismiss the medicine. It is a reason why the clinical assessment before starting, and the ongoing review during treatment, are designed the way they are. A prescriber reviewing how semaglutide works alongside your health history is doing exactly the work that helps predict and manage this variability. Worth knowing before you start rather than after.

The lifestyle variables that genuinely shift the numbers

Clinical trials of Wegovy always include dietary and activity support alongside the medicine. That is not a footnote; it is built into the design. In real-world use, people who maintain a reduced-calorie diet and keep up physical activity (particularly strength-based exercise) consistently achieve better outcomes than those who rely on the medicine alone.

Protein intake deserves particular attention. Semaglutide reduces overall appetite, which can inadvertently reduce protein consumption. Muscle mass matters for long-term metabolic rate, and inadequate protein intake during active weight loss may accelerate muscle loss. Staying well hydrated and keeping fibre intake up also tends to reduce the GI side effects that lead some people to reduce or stop their dose prematurely.

If you are considering the costs involved in private treatment, the Wegovy pricing page sets out what a typical private prescription includes and how to read the market honestly. A brief note on hair: some people ask whether their hair is thinning alongside weight loss on Wegovy, the answer is nuanced, and our page on hair loss on Wegovy covers what the evidence says.

What happens if Wegovy stops working, or never worked well enough

A plateau is common and does not always mean treatment has failed. Weight loss tends to slow or stall after the first year even in clinical trials, partly because the body adapts and partly because appetite suppression from semaglutide diminishes somewhat as weight falls. This is a known pharmacological pattern, not a sign that the medicine has stopped doing anything.

For people who genuinely see less than 5% weight loss after reaching and staying on the maintenance dose, NICE guidance is clear: continuing is reviewed with the prescriber. That review might look at whether the dose has been tolerated fully, whether lifestyle factors have been addressed, or whether an alternative medicine might suit better. The question of whether Wegovy works for everyone links directly to this: it does not, and a good clinical service should say so plainly.

If you are wondering what happens to your weight after stopping the medicine altogether, the evidence on that is also worth reading. Our page on weight regain after stopping Wegovy covers what studies show about what comes next. Making an informed decision means knowing both sides. If you would like a clinician to review whether Wegovy is the right option for you, you can start your free consultation with our prescribers today.